Meeting
2018 ASCO Annual Meeting
Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
Authors
Wenying Zhang
Bio-therapeutic Ward,Chinese PLA General Hospital, Beijing, China
Wenying Zhang , Yang Liu , Qian Mei , Lianjun Shen , Qingming Yang , WeiDong Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03346642
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7556)
DOI
10.1200/JCO.2018.36.15_suppl.7556
Abstract #
7556
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.
First Author: Chunmeng Wang
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2021 Genitourinary Cancers Symposium
Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).
First Author: Nathaniel Wilson